Loading...
Market
Which region will have the highest adoption rate of TECELRA® by end of 2025?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Sales and adoption reports from Adaptimmune
Story
FDA Grants Accelerated Approval to Adaptimmune's TECELRA® for Advanced Synovial Sarcoma
Aug 1, 2024, 06:03 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Adaptimmune's TECELRA® (afamitresgene autoleucel), marking it as the first approved engineered cell therapy for a solid tumor. This milestone approval extends the power of immunotherapies into difficult-to-reach sarcomas, specifically targeting advanced synovial sarcoma, a rare cancer that arises in the body's soft tissues. Adaptimmune's TECELRA® is also noted as a significant development in TCR gene therapy.
View original story
Similar markets
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other regions • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Africa • 25%
Asia • 25%
Latin America • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other Regions • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%